Antidepressants recall

A significant recall of over 80,000 packs of Sertraline was initiated on April 29, 2026, in the UK after a patient discovered Citalopram tablets inside a pack labeled for Sertraline. This incident highlights a critical medication error that raises concerns about patient safety in mental health treatment.

The recall was prompted by Amarox Limited as a precautionary measure. Both Sertraline and Citalopram are selective serotonin reuptake inhibitors (SSRIs) commonly prescribed to treat depression and anxiety. The error occurred during the secondary packaging process of the blister strips into cartons.

The total batch size involved in this recall is 81,872 packs, with the affected batch number being V2500425. In 2019 alone, more than 16.7 million prescriptions of Sertraline were issued by GPs in England, indicating the widespread use of this medication.

Dr. Alison Cave from the Medicines and Healthcare products Regulatory Agency (MHRA) advised patients who mistakenly took Citalopram instead of Sertraline to seek medical advice immediately. She noted that patients may experience heightened serotonergic side effects, which can include nausea, headache, sleep changes, and mild anxiety.

This recall underscores the importance of vigilance in pharmaceutical packaging processes to ensure patient safety. The potential risks associated with consuming incorrect medications can have serious implications for individuals relying on SSRIs for their mental health treatment.